Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

COVID-19 Study of the Serological Response Against the Severe Acute Respiratory Syndrome (SARS) Coronavirus 2 (CoV-2) Virus in 2 Types of Employees, Hospital and Non-hospital, at Institute Curie and Institute Pasteur (Curie-O-SA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04369066
Recruitment Status : Active, not recruiting
First Posted : April 30, 2020
Last Update Posted : May 19, 2021
Sponsor:
Information provided by (Responsible Party):
Institut Curie

Brief Summary:

This research proposes to study a large healthy population active for the presence of antibodies directed against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus and this over time.

After verification of the inclusion criteria and information by the coordinating investigative doctor, the volunteers sign a written consent. A nurse will take blood samples under safe conditions compatible with the pandemic period and while respecting the protection of the volunteer's personal data.

The blood samples will be taken at 4 times for Institute Curie and Institute Pasteur: T0 (day of inclusion), between 6 weeks and 3 months ,6 months and 12 months post-inclusion.

Each blood sample consists of a collection of 5 mL of blood in a dry tube. The serum samples will be extracted and collected prospectively from the blood samples.

The nasopharyngeal swabs will be performed at 3 times: , between 6 weeks and 3 months, 6 months and 12 months post-inclusion for Institute Curie staff who have had at least one of the following four criteria on the sample or questionnaire carried out at T0:

  • have had RT-PCR+
  • and/or presence of antibodies at the 95% threshold
  • and/or anosmia/ageusia
  • and/or digestive syndrome with associated respiratory signs. In case of infection between sampling times, if the volunteer meets one of the four criteria above, a nasopharyngeal swab will be performed during the following visits.

The nasopharyngeal swab shall also be proposed to volunteers not meeting the 4 above listed criteria in order to have a control group (about 100 volunteers) for future statistical analyses.

If the volunteers accept, naso-pharyngeal swab shall be performed between 6 weeks and 3 months, 6 months and 12 months after inclusion.

For volunteers already included at Institute Curie : in case of proved (RT-PCR+ or antigenic +) or very likely (anosmia and/or ageusia, and/or digestive syndrome with associated respiratory signs) between 2 sampling times already planned in the flow chart, blood samples and nasopharyngeal swabs shall be performed.

Those shall be performed if time since last planned sampling(s) has been more than 3 weeks or if time until next sampling(s) is more than 3 weeks.

The blood samplings and nasopharyngeal swabs will be performed at 4 times for Institute Pasteur personnel: at T0 (inclusion day), between 6 weeks and 3 months, at 6 months and 12 months post-inclusion


Condition or disease Intervention/treatment Phase
Volunteers From the Institute Curie and Institute Pasteur Staff Who Are Not Showing Active SARS-CoV-2 Infection Diagnostic Test: Blood samples (collection of 5 mL of blood in a dry tube) Diagnostic Test: Nasopharyngeal swabs Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1971 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Health Services Research
Official Title: COVID-19 Study of the Serological Response Against the SARS-CoV-2 Virus in 2 Types of Employees, Hospital and Non-hospital, at Institute Curie and Institute Pasteur
Actual Study Start Date : April 28, 2020
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : February 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Subjects who are not showing active SARS-Cov2 infection Diagnostic Test: Blood samples (collection of 5 mL of blood in a dry tube)

A nurse will take blood samples under safe conditions compatible with the pandemic period and while respecting the protection of the volunteer's personal data.

The blood samples will be taken at 4 times for Institute Curie and Institute Pasteur: T0, between 6 weeks and 3 months ,6 months and 12 months post-inclusion.

For volunteers already included at Institute Curie : in case of proved (RT-PCR+ or antigenic +) or very likely (anosmia and/or ageusia, and/or digestive syndrome with associated respiratory signs) between 2 sampling times already planned in the flow chart, blood samples shall be performed, if time since last planned sampling(s) has been more than 3 weeks or if time until next sampling(s) is more than 3 weeks.

The serum samples will be extracted and collected prospectively from the blood samples.

For each blood sample, a sample number will be assigned by the laboratory management system of the Department of Biology at Institut Curie.


Diagnostic Test: Nasopharyngeal swabs

The nasopharyngeal swabs will be performed between 6 weeks and 3 months, 6 months and 12 months post-inclusion for Institute Curie staff with at least one of the following criteria: have had RT-PCR+, and/or presence of antibodies at the 95% threshold, and/or anosmia/ageusia, and/or digestive syndrome with associated respiratory signs.

The nasopharyngeal swab shall also be proposed to volunteers not meeting the above listed criteria to have a control group (about 100 volunteers).

For volunteers already included at Institute Curie : in case of proved (RT-PCR+ or antigenic +) or very likely (anosmia and/or ageusia, and/or digestive syndrome with associated respiratory signs) infection between 2 sampling times, nasopharyngeal swabs shall be performed if time since last planned sampling(s) has been more than 3 weeks or if time until next sampling(s) is more than 3 weeks.

The nasopharyngeal swabs will be performed at T0 for Institute Pasteur staff so 4 times in total.





Primary Outcome Measures :
  1. Antibodies against the SARS-CoV-2 virus in serum at inclusion [ Time Frame: 1 day ]
    Detection of antibodies against the SARS-CoV-2 virus with serological tests

  2. Antibodies against the SARS-CoV-2 virus in serum at 1 month [ Time Frame: 1 month ]
    Detection of antibodies against the SARS-CoV-2 virus with serological tests

  3. Antibodies against the SARS-CoV-2 virus in serum at 3 months [ Time Frame: 3 months ]
    Detection of antibodies against the SARS-CoV-2 virus with serological tests

  4. Antibodies against the SARS-CoV-2 virus in serum at 6 months [ Time Frame: 6 months ]
    Detection of antibodies against the SARS-CoV-2 virus with serological tests

  5. Antibodies against the SARS-CoV-2 virus in serum at 12 months [ Time Frame: 12 months ]
    Detection of antibodies against the SARS-CoV-2 virus with serological tests


Secondary Outcome Measures :
  1. Comparative performance of anti-SARS-CoV-2 antibody detection techniques [ Time Frame: 9 months ]
    Comparative performance of anti-SARS-CoV-2 antibody detection techniques (sensitivity and specificity of serological tests)

  2. Prevalence of immune subjects for SARS-CoV-2 [ Time Frame: 3 months ]
    Prevalence of immune subjects for SARS-CoV-2 in a well-defined active healthy population, working at the hospital or not, leading to variable exposure levels

  3. Nature and quantity of anti-SARS-CoV-2 antibodies [ Time Frame: 3 months ]
    Nature and quantity of anti-SARS-CoV-2 antibodies: ImmunoglobulinM, ImmunoglobulinG and ImmunoglobulinA)

  4. Evolution of the different antibodies against the SARS-CoV-2 virus over time. [ Time Frame: 6 months ]
    The analysis of the evolution of serology results over time will be done by a mixed model taking into account the repeated framework of the data of a subject

  5. Prevalence of Anti-covid IgA response in the nasal mucosa [ Time Frame: 6 months ]
    Prevalence of Anti-covid IgA in volonteers RT/PCR+ and/or presence of antibodies at the 95 % threshold and/or COVID symptoms



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Person, adult volunteer outside of any acute infectious episode with SARS-CoV-2* (see paragraph indication), working at the Institute Curie and able to exercise their professional activity on one of the 3 sites of the Institute Curie: Paris, Orsay or Saint Cloud, or on the Campus of the Institute Pasteur.
  2. Person aged 18 or over.
  3. Information and consent of the person to the procedures related to the study (cf. information note / consent).

From November 2020, person having presented at least one of the following criteria since January 2020:

  • A positive diagnostic test for SARS-COV-2 by PCR on a nasopharyngeal sample or antigenic test,
  • A positive SARS-CoV-2 serology,
  • An anosmia or / and an ageusia,
  • A respiratory infection ** associated with digestive signs **

whatever the working methods during confinement * Subjects who are not showing active SARS-CoV-2 infection are considered volunteers at the time of inclusion: people with no clinical signs ** suggestive of SARS-CoV-2 infection at the time of collection or having had an end of symptoms for more than 7 days [1].

** fever, fatigue, cough, shortness of breath, difficulty to breath, loss of taste or smell, headache, body aches, conjunctivitis or cold, digestive problems (vomiting, diarrhea), whether or not the signs led to sick leave, treatment and / or hospitalization [2].

Exclusion Criteria:

  • Declaration by the subject of signs suggestive of Coronavirus Infectious Disease 2019 (COVID-19) infection with SARS-CoV-2 in progress or for which the end of symptoms dates from less than 7 days
  • Inability to submit to study monitoring for geographic, social or psychological reasons

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04369066


Locations
Layout table for location information
France
Institut Curie
Paris, France, 75005
Institut Pasteur
Paris, France, 75015
Sponsors and Collaborators
Institut Curie
Investigators
Layout table for investigator information
Study Director: Pierre Fumoleau, PhD Institut Curie
Layout table for additonal information
Responsible Party: Institut Curie
ClinicalTrials.gov Identifier: NCT04369066    
Other Study ID Numbers: IC 2020-07
First Posted: April 30, 2020    Key Record Dates
Last Update Posted: May 19, 2021
Last Verified: May 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Institut Curie:
Adults
Volunteers